SLNO · Soleno Therapeutics Inc
Market Cap
$2.76B
Shares
52.12M
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Limited
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-10% holders QoQ · +44 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.45% of float · ▼ -32.5% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
228 holders — mid 3-yr range
Fundamentals
Revenue growth
+139%
Y/Y
Gross margin
-4%
contracting
EPS growth
+109%
Y/Y
Free cash flow
$46.7M
Buyback
$100.0M
authorized
Balance sheet
$20.2M
net cash
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active patients on drug | 859 | as of December 31, 2025 | — |
| cash flow from operating activities | $48.7M | the fourth quarter | — |
| invested in accelerated share repurchase program | $100M | the year ended December 31, 2025 | — |
| lives covered | 185M | from approval on March 26, 2025 through December 31, 2025 | — |
| new prescribers in the fourth quarter | 136 | the fourth quarter | — |
| patient start forms received | 1,250 | from approval on March 26, 2025 through December 31, 2025 | — |
| patient start forms received (fourth quarter) | 207 | the fourth quarter | — |
| unique prescribers | 630 | from approval on March 26, 2025 through December 31, 2025 | — |
| Discontinuation rate of VYKAT XR related to adverse events | 12% | fourth quarter 2025 | — |
| Lives covered as percentage of total lives | 60% | from launch through December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLNO
this stock
Soleno Therapeutics Inc
|
$2.76B | — | +138.8% | — | 8.5% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events